Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation

AIMS: VENTURE-AF is the first prospective randomized trial of uninterrupted rivaroxaban and vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation (CA). METHODS AND RESULTS: Trial size was administratively set at 250, the protocol-specified...

Descripción completa

Detalles Bibliográficos
Autores principales: Cappato, Riccardo, Marchlinski, Francis E., Hohnloser, Stefan H., Naccarelli, Gerald V., Xiang, Jim, Wilber, David J., Ma, Chang-Sheng, Hess, Susanne, Wells, Darryl S., Juang, George, Vijgen, Johan, Hügl, Burkhard J., Balasubramaniam, Richard, De Chillou, Christian, Davies, D. Wyn, Fields, L. Eugene, Natale, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
FASTTrack Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508487/
https://www.ncbi.nlm.nih.gov/pubmed/25975659
http://dx.doi.org/10.1093/eurheartj/ehv177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508487/
https://www.ncbi.nlm.nih.gov/pubmed/25975659
http://dx.doi.org/10.1093/eurheartj/ehv177

Ejemplares similares